Apr 08, 2021 06:28 UTC
  • US begins study on allergic reactions to Pfizer, Moderna COVID-19 vaccines after serious reactions reported

The United States has begun study on allergic reaction risk in Pfizer and Moderna vaccines as doubts grow over full efficacy of the American COVID-19 vaccines.

The US National Institutes of Health said Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to Pfizer/BioNTech and Moderna vaccinations.

According to Press TV, this came after such reactions, including life-threatening episodes, known as anaphylaxis, were reported in the United States after vaccinations of Pfizer and Moderna shots.

 “The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines,” said Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

“The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving these two vaccines,” Fauci noted.

In January, the US Centers for Disease Control and Prevention said allergic reactions are occurring at a rate of over 11 per one million vaccinations.

The Pfizer-BioNTech and Moderna vaccines are the first two COVID-19 vaccines authorized by the US Food and Drug Administration for emergency use and already have been given to millions of Americans.

Most of the severe allergic reactions to these vaccines have occurred in people with a history of allergies. A substantial number of these people had previously experienced a anaphylaxis reaction.

The NIAID-funded study will enroll 3,400 adults between the ages of 18 to 69, with about 60% participants having a history of severe allergic reactions to food, insect stings or immunotherapy.

The goal of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes after injection.